- WACKER SUPPORTS CUREVAC IN THE PRODUCTION OF ITS MRNA-BASED VACCINE CANDIDATE AGAINST COVID-19
- MANUFACTURING AT WACKER´S BIOTECH SITE IN AMSTERDAM IS SCHEDULED TO START IN THE FIRST HALF OF 2021
För mer information se bifogad pressrelease.
För mer information se bifogad pressrelease.